Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICOSLG | O75144 | 10/20 | 0.55 |
| ▸ | ICOS | Q9Y6W8 | 10/20 | 0.55 |
| ▸ | CHUK | O15111 | 15/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.41 |
| ▸ | IKBKG | Q9Y6K9 | 1/20 | 0.41 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12653119 | 0.93 | ICOSLG (0.58) | ICOSLGICOSCHUKMEN1IKBKB | |
| SCHEMBL12619727 | 0.93 | ICOSLG (0.58) | ICOSLGICOSCHUKMEN1IKBKB | |
| SCHEMBL12619689 | 0.92 | ICOSLG (0.57) | ICOSLGICOSCHUKMEN1IKBKB | |
| SCHEMBL1798347 | 0.91 | ICOSLG (0.56) | ICOSLGICOSCHUKMEN1IKBKB | |
| SCHEMBL12619445 | 0.91 | ICOSLG (0.56) | ICOSLGICOSCHUKMEN1IKBKB | |
| SCHEMBL12619613 | 0.91 | ICOSLG (0.58) | ICOSLGICOSCHUKMEN1IKBKB | |
| SCHEMBL1811915 | 0.91 | ICOSLG (0.59) | ICOSLGICOSCHUKMEN1IKBKB | |
| SCHEMBL12619438 | 0.91 | ICOSLG (0.59) | ICOSLGICOSCHUKMEN1IKBKB | |
| SCHEMBL12619721 | 0.91 | ICOSLG (0.55) | ICOSLGICOSCHUKMEN1IKBKB | |
| SCHEMBL13270202 | 0.91 | ICOSLG (0.58) | ICOSLGICOSCHUKMEN1IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951801-B2 | For therapy of inflammatory disease and cancer | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-7951801-B2 | For therapy of inflammatory disease and cancer | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| EP-2206713-A1 | Beta-carbolines useful for treating inflammatory disease | Millennium Pharmaceuticals, Inc. (US) | 2010-07-14 | — | — | EP | disclosed |